Skip to main content

Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
NCT05130970 | Phase 2 | Interventional

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

Trial Information
20 Sites
80 Participants
40 Years

If interested, contact for more information

The University of Alabama at Birmingham
Birmingham, Alabama, 35205, United States
Pulmonary Associates Clinical Trials AZ
Phoenix, Arizona, 85032, United States
National Institute of Clinical Research
Huntington Beach, California, 92647, United States
University of Southern California Center for Advanced Lung Disease
Los Angeles, California, 90033, United States
Meris Clinical Research
Brandon, Florida, 33511, United States
Lakes Research
Miami Lakes, Florida, 33014, United States
Reliant Medical Research
Miami, Florida, 33165, United States
US Associates in Research LLC
Miami, Florida, 33175, United States
Renstar Medical Research
Ocala, Florida, 34471, United States
Central Florida Pulmonary Group, PA
Orlando, Florida, 32803, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Jadestone Clinical Research
Silver Spring, Maryland, 20904, United States
Hannibal Clinic
Hannibal, Missouri, 63401, United States
Southeastern Research Center
Winston-Salem, North Carolina, 27103, United States
University of Cincinnati
Cincinnati, Ohio, 45267, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Temple University TMS
Philadelphia, Pennsylvania, 19140, United States
Clinical Trial Center of Middle Tennesse
Franklin, Tennessee, 37067, United States
Baylor Scott and White Health Advanced Lung Disease Specialists
Dallas, Texas, 75246, United States
Baylor College of Medicine
Houston, Texas, 77030, United States

Study Eligibility Criteria

  • Male or female patients ≥ 40 years of age
  • Documented diagnosis of IPF
  • History of clinically significant cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina during the 6 months before screening
  • Sinoatrial or atrioventricular block, uncontrolled hypertension
  • Active bleeding or current clinically significant coagulopathy

Additional Studies

Additional studies can be found at